Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) – Equities researchers at Lifesci Capital cut their FY2022 earnings per share (EPS) estimates for shares of Pyxis Oncology in a research note issued to investors on Tuesday, November 1st. Lifesci Capital analyst A. Evertts now forecasts that the company will post earnings of ($4.17) per share for the year, down from their previous forecast of ($3.73). The consensus estimate for Pyxis Oncology's current full-year earnings is ($3.41) per share.

Pyxis Oncology Stock Down 3.8 %

Shares of Pyxis Oncology stock opened at $1.53 on Friday. Pyxis Oncology has a 52 week low of $1.49 and a 52 week high of $13.75. The business's fifty day simple moving average is $2.04 and its 200-day simple moving average is $2.39.

Institutional Trading of Pyxis Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Laurion Capital Management LP boosted its stake in Pyxis Oncology by 159.9% during the second quarter. Laurion Capital Management LP now owns 3,170,803 shares of the company's stock worth $7,547,000 after buying an additional 1,950,971 shares during the period. Credit Suisse AG acquired a new position in shares of Pyxis Oncology in the 2nd quarter worth approximately $2,298,000. Tekla Capital Management LLC boosted its position in shares of Pyxis Oncology by 424.7% during the 1st quarter. Tekla Capital Management LLC now owns 708,303 shares of the company's stock worth $2,630,000 after purchasing an additional 573,303 shares during the period. Acuta Capital Partners LLC increased its holdings in Pyxis Oncology by 222.6% in the 2nd quarter. Acuta Capital Partners LLC now owns 645,149 shares of the company's stock valued at $1,535,000 after purchasing an additional 445,149 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Pyxis Oncology by 1.2% in the first quarter. Vanguard Group Inc. now owns 526,309 shares of the company's stock valued at $2,126,000 after buying an additional 6,011 shares in the last quarter. 71.59% of the stock is currently owned by hedge funds and other institutional investors.

About Pyxis Oncology

(Get Rating)

Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

Read More

• Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
• MarketBeat: Week in Review 10/31-11/4
• Is Hershey's a Sweet Stock to Buy After a Post-Earnings Dip?
• Datadog Doesn't Belong In The Doghouse
• Mixed Results Actually Bring More Optimism than Risk for AMD
• Nikola Shares Fall Even As EV Maker Beats Q3 Expectations

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.